Related Experiment Video
Updated: May 7, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Impact of initial clinical presentation on clopidogrel low response
Jean-Baptiste Landel1, Anne Bauters, Cédric Delhaye
1Unité des soins intensifs de cardiologie, centre hémodynamique, clinique de cardiologie, hôpital cardiologique, centre hospitalier régional et universitaire de Lille, boulevard du Pr-Jules-Leclercq, 59037 Lille cedex, France.
Archives of Cardiovascular Diseases
|September 28, 2013
Summary
Acute coronary syndromes (ACS) significantly increase clopidogrel low response compared to stable coronary artery disease. This highlights the impact of initial clinical presentation on antiplatelet therapy effectiveness.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Clopidogrel response exhibits significant interindividual variability.
- Low clopidogrel response is linked to adverse outcomes post-percutaneous coronary intervention.
- Variability in clopidogrel response may also occur within individuals over time.
Purpose of the Study:
- To evaluate how initial clinical presentation affects clopidogrel low response.
- To compare clopidogrel response in patients with acute coronary syndromes versus stable coronary artery disease.
Main Methods:
- Prospective study of 100 patients, divided into acute coronary syndromes (ACS) and stable coronary artery disease groups.
- Clopidogrel response assessed 18-24 hours post-loading dose using VerifyNow-P2Y12 (platelet reaction units [PRUs]).
- Exclusion criteria included chronic clopidogrel therapy or use of specific other antiplatelet/anticoagulant agents.
Main Results:
- The ACS group showed significantly higher mean PRU values (197 ± 81) compared to the stable group (159 ± 94; p=0.03).
- Multivariable analysis identified the ACS presentation as a significant predictor of higher PRU values (p=0.02).
- Clopidogrel low responders (PRU > 230) were more frequent in the ACS group (38%) than in the stable group (18%; p=0.04).
Conclusions:
- Initial clinical presentation, particularly acute coronary syndromes (ACS), is a strong predictor of clopidogrel low response.
- Patient's evolving coronary artery disease influences clopidogrel response over time.
- Findings support more aggressive antiplatelet strategies for ACS patients, aligning with recent trial outcomes.
Keywords:
ACSADPAcute coronary syndromesAngioplastie coronaire percutanéeAntiagrégant plaquettaireAntiplatelet therapyBMIClopidogrel responsePCIPRUPercutaneous coronary interventionRéponse au clopidogrelSyndrome coronaire aiguVerifyNow-P2Y12acute coronary syndromesadenosine diphosphatebody mass indexpercutaneous coronary interventionplatelet reaction unitRelated Concept Videos
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...